A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Evaluating the Efficacy and Long-Term Safety of Tirzepatide Once Weekly Compared to Placebo in Adults With Type 1 Diabetes and Obesity or Overweight
Latest Information Update: 03 Jun 2025
At a glance
- Drugs Tirzepatide (Primary)
- Indications Obesity; Type 1 diabetes mellitus
- Focus Registrational; Therapeutic Use
- Acronyms SURPASS-T1D-2
- Sponsors Eli Lilly and Company
Most Recent Events
- 29 May 2025 Status changed from not yet recruiting to recruiting.
- 16 May 2025 New trial record